| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Vivos Therapeutics, Inc.$0.43
+0 (+1.05%)
Market Cap
8.48 M
EPS
-2.31
P/E Ratio
-
Value Trade
95.56 K
SEC Financials
Q1 2026Dilution Risk
Revenue
5.14 M
Operating CF
-6.01 M
Total Assets
25.04 M
Total Liabilities
26.31 M
Equity
-1.14 M
-11.59 %
Week
-41.9 %
1 Month
-62.8 %
3 Month
-71.5 %
6 Month
-99.57 %
5 Year
-99.65 %
All Time
Cash Data
Cash Position
2.11 M
Monthly Burn
2.00 M
Runway
0 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
66.23 K
52 Week Range
0.55 - 7.95
% held by Insiders
24.7 %
% held by Institutions
13.12 %
Enterprise Value
18.50 M
Total Shares
13.61 M
Short %
11.51 %
Float Shares
10.73 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Vivos DNA appliance | pediatric obstructive sleep apnea | — | 2025-09-17 | 20–40% of pediatric patients — with symptoms recurring in up to a quarter of cases Read More | Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment Read More | |
Vivos DNA appliance | pediatric obstructive sleep apnea | — | 2025-09-17 | 20–40% of pediatric patients — with symptoms recurring in up to a quarter of cases Read More | Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment Read More | |
Vivos DNA appliance | pediatric obstructive sleep apnea | — | 2025-09-17 | 20–40% of pediatric patients — with symptoms recurring in up to a quarter of cases Read More | Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VVOS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VVOS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VVOS▼ -19.6%on this news
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Therapeutics has extended its strategic financing agreement with Streeterville Capital until August 31, 2026. This extension allows Vivos more time to raise necessary equity while reaffirming Streeterville's commitment to convert up to $4.5 million of debt into equity. The management believes this will facilitate a more organized capital-raising process.
Read more →VVOSVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics plans to file a registration statement for a proposed rights offering, aiming to distribute subscription rights to shareholders. The offering is contingent on SEC approval, with rights expected to be exercisable for nine months. Management highlights the potential for additional capital to support operations, though uncertainties remain regarding completion.
Read more →VVOSVivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet Manufacturing
Vivos Inc. has received its Washington State Radioactive Materials License for the manufacturing of IsoPet®, a development that marks a significant regulatory milestone for the company's animal health division. This license allows for in-house production at Vivos' new facility in Richland, Washington, facilitating the expansion of certified IsoPet® treatment centers nationwide. The company plans to quickly begin production and anticipates shipping its first units in the near future, enhancing access to precise cancer therapies for companion animals and horses.
Read more →VVOS▼ -8.8%on this newsshared move
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics has entered a collaboration with South Palm Cardiovascular Associates to form AIM Florida, aimed at improving diagnosis and treatment for patients with obstructive sleep apnea and insomnia who also suffer from cardiovascular disease. This partnership seeks to enhance patient care and expand access to integrated services in Florida. Vivos anticipates that this model could be replicated across the country, although there are uncertainties regarding the finalization of agreements and operational execution.
Read more →VVOSVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City. CEO Kirk Hunstman is set to deliver a corporate presentation and engage in one-on-one meetings with investors. This event aims to highlight investment opportunities among micro and small-cap companies.
Read more →VVOS▲ +24.8%on this newsshared move
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics has announced a binding agreement with Streeterville Capital to convert up to $4.5 million of its senior debt into preferred and common stock. This transaction, aimed at improving the company's financial health, includes commitments to suspend repayment obligations temporarily. The success of this exchange relies on the completion of additional equity financings, which carries inherent risks. Overall, this initiative is part of Vivos' strategy to comply with Nasdaq listing standards and enhance liquidity.
Read more →VVOSVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics reported a 70% year-over-year increase in revenue for Q1 2026, amounting to approximately $5.1 million. The firm attributed this growth primarily to its acquisition of The Sleep Center of Nevada and the successful implementation of its new business model. While gross profit also increased significantly, the company recorded a net loss of $7.8 million, attributed to rising operating expenses and the costs related to business expansion. Vivos emphasized its commitment to restructuring and improving cash flow as it works to solidify growth.
Read more →VVOS▼ -25.9%on this news
Vivos Therapeutics Reports Full Year 2025 Financial Results
Vivos Therapeutics reported a 16% revenue increase for the full year 2025, driven by a strategic shift towards integrating sleep specialty providers. Despite an operating loss from investments in this new model, management remains optimistic about achieving cash flow positivity by year-end. The company continues to innovate in the treatment of obstructive sleep apnea.
Read more →VVOS▲ +8.9%on this news· ran to -25% by day 3shared move
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
Vivos Therapeutics (NASDAQ: VVOS) has announced plans to release its full year 2025 financial results on April 15, 2026, followed by a conference call to discuss these results and operational updates. The call will address Vivos' strategic collaborations and their expected impact on revenue growth. The company focuses on innovative treatments for obstructive sleep apnea (OSA) and has FDA-cleared devices for patients of all ages. However, Vivos also raises caution regarding the risks associated with revenue strategies and patient outcomes.
Read more →VVOS▼ -5.3%on this news
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Vivos Therapeutics, Inc. has completed a private placement with V-Co Investors 3 LLC, securing $2.25 million to support its operations and growth. This funding comes amidst increased confidence from New Seneca Partners, who have previously invested a total of $13.4 million in Vivos. The company plans to use the proceeds for general working capital while continuing to enhance its distribution model for sleep-related health solutions. CEO Kirk Huntsman expressed gratitude for Seneca's ongoing support and outlined goals for achieving breakeven operating cash flow by the end of 2026.
Read more →VVOSVivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics has achieved in-network status with several commercial health insurers and Medicare in Nevada, enhancing access to its OSA treatments for patients. This development is expected to significantly boost patient volume and revenue. Additionally, Vivos is implementing cost reduction measures aimed at saving $4 million annually, which will help reduce its cash burn rate. The company anticipates that these changes will support its goal of becoming cash flow positive in 2026.
Read more →VVOSRecent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
Vivos Therapeutics announced a study confirming the link between dental morphology and obstructive sleep apnea (OSA) severity. The study, involving 100 participants, showed that specific craniofacial features correlate with OSA, supporting Vivos' treatment approach. Vivos CARE devices, cleared by the FDA, have successfully treated many patients, reducing reliance on traditional therapies like CPAP.
Read more →VVOSVivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Vivos Therapeutics has partnered with SoundHealth to distribute innovative allergy and sleep health technologies. This collaboration will utilize Vivos' extensive network of trained providers to enhance public access to SoundHealth's FDA-cleared products, including the Sonu Band and Spatial Sleep band. Both devices aim to improve airway health and sleep quality through advanced technology.
Read more →VVOSVivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals
Vivos Inc. has announced the issuance of U.S. Patent No. 12,521,452 B2 for its innovative cancer treatment technology, enhancing its proprietary Precision Radionuclide Therapy™ platform. The patent protects a novel thermogel suspension that enables precise radiation delivery into tumors while minimizing exposure to healthy tissues. Additionally, the company's PRECISIONGEL™ trademark has been approved in the U.S. and New Zealand, and a new patent application has been filed to expand the use of the hydrogel for therapeutic agents. These developments bolster Vivos' intellectual property position and support its growth strategy.
Read more →VVOS▼ -7.1%on this news
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics has successfully closed the exercise of warrants, generating approximately $4.64 million in gross proceeds. The company issued new unregistered warrants in a private placement to facilitate this process. The funds will be utilized for working capital and corporate purposes, as Vivos continues to focus on innovative solutions for obstructive sleep apnea.
Read more →VVOSVivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics has announced the exercise of warrants, generating approximately $4.64 million in gross proceeds. The company will issue new unregistered warrants as part of this transaction, which is expected to close around January 20, 2026. The funds will be used for working capital and general corporate purposes, supporting Vivos' ongoing efforts in treating sleep-related disorders.
Read more →VVOSVivos Inc Summarizes Progress in its Animal Therapy Division
Vivos Inc. reported significant progress in its IsoPet division, highlighting a 1,200% year-over-year increase in administered therapies from 2024 to 2025. The company plans to implement profitability-focused initiatives and expand its certified clinic network, which now includes 17 clinics. With two new certifications, IsoPet therapy is becoming more widely available for both small and equine animals. A partnership with Exubrion Therapeutics aims to enhance its presence in the equine oncology market, with several successful treatments reported.
Read more →VVOSVivos Inc Summarzes Preogress in its Animal Therapy Division
Vivos Inc. has reported significant progress in its IsoPet division, with an 800% increase in administered therapies year-over-year from 2024 to 2025. The division has been successful in scaling treatment options, performing over 100 therapies across various animal species, and expanding its clinic network. New certifications in Texas and Florida enable broader access to IsoPet therapy, and a partnership with Exubrion Therapeutics is poised to boost its presence in the equine oncology segment. The company is focused on profitability and data-driven marketing strategies as it approaches the year 2026.
Read more →VVOSVivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep Solut
Vivos Therapeutics has announced the grand opening of a new affiliated sleep testing and treatment center in Auburn Hills, Michigan, as part of its strategy to expand operations. This center will operate under a commercial alliance with MISleep Solutions, providing diagnostic and therapeutic services for obstructive sleep apnea (OSA). The affiliation model aims to capitalize on high-volume patient flows while offering innovative treatment options, which may improve patient outcomes. Vivos also plans to establish similar partnerships with other practitioners in the metro Detroit area and beyond as part of its growth plan.
Read more →VVOSVivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
Vivos Therapeutics will participate in an online fireside chat on December 16, 2025, featuring CEO Kirk Huntsman and CFO Brad Amman. They will discuss the company's strategic business model, market opportunities, and financial strategies. The event aims to engage investors and highlight Vivos' innovative approaches to treating sleep-related breathing disorders.
Read more →VVOS▼ -10.2%on this news
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
Vivos Therapeutics reported a significant 78% sequential revenue growth in Q3 2025, attributed to the successful integration of the Sleep Center of Nevada. The company is optimistic about future growth as it expands its operations and services in response to increasing patient demand. Management is actively pursuing additional market opportunities and optimizing existing operations.
Read more →VVOSVivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. plans to release its third quarter 2025 financial results and conduct a conference call on November 19, 2025. The call will cover operational updates and strategic collaborations that may impact revenue growth. Vivos specializes in innovative treatments for sleep-related breathing disorders, including obstructive sleep apnea.
Read more →VVOSVivos Inc. Issues Shareholder Update Letter
Vivos Inc. is actively pursuing FDA Investigational Device Exemption (IDE) approval to start human clinical studies at Mayo Clinic, focusing on the precision delivery of their RadioGel product. The company has engaged regulatory expert John Smith to refine their submission strategy based on FDA feedback. Additionally, Vivos has established Vivos Scientific India LLP to expand their operations in India, where they aim to accelerate product approval and commercialization. Positive growth is observed in their IsoPet division, with a reported 800% increase in therapies administered from 2024 to 2025.
Read more →VVOSVivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics
Vivos Inc. has announced an expanded collaboration with Exubrion Therapeutics to utilize targeted radioactive isotope technology for various veterinary applications. The partnership aims to enhance their joint efforts in areas such as licensing, shared clinic relationships, and manufacturing optimization. Both companies emphasize their complementary strengths, with Vivos focusing on cancer therapies and Exubrion on osteoarthritis treatments in companion animals. This collaboration is seen as a pivotal step toward advancing innovation in veterinary therapeutic technologies.
Read more →VVOSVivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Vivos Therapeutics has released new clinical data demonstrating that its FDA-cleared Daytime-Nighttime Appliance (DNA) significantly improves symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children suffering from obstructive sleep apnea (OSA). The study showed a notable reduction in ADHD symptoms and sleep-disordered breathing, suggesting a promising non-surgical treatment alternative. The findings indicate that addressing OSA may lead to better behavioral outcomes in affected children.
Read more →VVOSVivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Vivos Therapeutics has announced positive results from a multicenter clinical trial demonstrating the safety and efficacy of its Vivos DNA appliance for treating pediatric obstructive sleep apnea (OSA). The findings, published in the European Journal of Pediatrics, suggest a promising non-surgical alternative to the invasive adenotonsillectomy. This breakthrough could significantly impact the treatment landscape for the estimated 10 million U.S. children affected by OSA.
Read more →VVOS▼ -7%on this news
Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy
Vivos Inc. has announced new data affirming the precision of its Precision Radionuclide Therapy, specifically with its products RadioGel® and IsoPet®. The high therapeutic ratio achieved in clinical studies minimizes damage to healthy tissue while effectively targeting tumors, a factor that has led to FDA Breakthrough Device designation. Notably, clinical trials demonstrated successful treatments of tumors in both horses and humans without adverse effects. Vivos Inc. continues to develop its innovative cancer therapies, aspiring to expand its market presence significantly.
Read more →VVOS▲ +7.1%on this newsshared move
Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization
Vivos Inc. has filed a provisional patent for a new electron beam sterilization process for its hydrogel, achieving rigorous sterility levels necessary for critical medical applications. This validated process promises greater manufacturing efficiency, cost-effectiveness, and enhanced scalability for Vivos' products targeting both human and animal health. The strategic move is expected to strengthen the company's market position and revenue opportunities while providing improved safety standards in its therapies. This dual-benefit approach positions Vivos for significant growth in the competitive biopharma landscape.
Read more →VVOS▲ +10.1%on this news
R.D. PRABHU, LATA K. SHETE, M.D.s FINANCIAL STATEMENTS DECEMBER 31, 2024 and 2023 R.D. PRABHU, LATA K. SHETE, M.D. DECEMBER 31, 2024 and 2023 TABLE OF CONTENTS PAGE NO. INDEPENDENT AUDITORS' REPORT 1 - 2 FINANCIAL STATEM
R.D. Prabhu and Lata K. Shete's financial statements for The Sleep Center of Nevada for the years ending December 31, 2023, and 2024 show a notable increase in net income and total assets. The organization reported a net income of $729,464 in 2024, up significantly from $78,336 in 2023. Despite positive earnings, there are concerns over cash flow management and increasing liabilities that may affect future operations.
Read more →VVOSVivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Vivos Therapeutics reported strong second-quarter results, highlighted by the acquisition of The Sleep Center of Nevada, which has generated significant revenue and patient demand for its OSA treatments. The company is pivoting its business model to enhance direct patient relationships and is exploring further acquisitions. Despite some challenges with capacity and legacy revenue, management remains optimistic about future growth.
Read more →VVOSVivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. plans to release its second quarter 2025 financial results on August 19, 2025, followed by a conference call to discuss the results and recent developments. The company specializes in treatments for sleep-related breathing disorders, including obstructive sleep apnea. Vivos' innovative solutions aim to address a significant global health issue, although they face integration and regulatory challenges.
Read more →VVOSVivos Therapeutics Adds to Management Team to Support Expansion and Growth
Vivos Therapeutics has appointed Michael Bruhn as Executive VP of Business Operations Integration and Dr. Terry Jones as Senior VP of Human Resources to support its growth and expansion efforts. These appointments are part of Vivos' strategy to enhance its operations and integrate new acquisitions, including the recent acquisition of The Sleep Center of Nevada. Both leaders bring extensive experience to help Vivos tackle the challenges of obstructive sleep apnea treatment.
Read more →VVOS▲ +22.5%on this news· ran to +64% by day 3
Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
Vivos Therapeutics has received Medicare approval for its VidaSleep™ oral appliance, designed for treating mild to moderate obstructive sleep apnea (OSA). This approval is expected to increase accessibility for millions of Medicare beneficiaries and encourages private insurers to follow suit. The VidaSleep™ device, along with the mmRNA® appliance, positions Vivos uniquely in the sleep therapy market, addressing the needs of a significant patient population.
Read more →VVOSVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada Transaction brings OSA diagnostic revenue to Vivos plus Vivos' highly effective OSA treatment options to thousands of potential patients in the great
Vivos Therapeutics, Inc. has successfully completed its acquisition of The Sleep Center of Nevada, significantly enhancing its position in the obstructive sleep apnea (OSA) space. This acquisition is expected to increase revenue through OSA diagnostics and the distribution of Vivos' patented treatments to a broader patient base. The deal also marks a pivotal shift in Vivos' business strategy from a focus on dental providers to medical sleep practices, enabling the capture of higher-margin revenues. Vivos has secured $11 million in new financing through loans and investments to support this transition.
Read more →VVOS▲ +5.2%on this newsshared move
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Vivos Therapeutics has successfully acquired The Sleep Center of Nevada, expanding its reach in the obstructive sleep apnea (OSA) market. This acquisition aligns with Vivos' strategic pivot towards high patient volume centers, enhancing revenue potential. The company secured over $11 million in financing to support this transition and aims to integrate SCN's operations to provide effective OSA treatments directly to patients.
Read more →VVOSVivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for
Vivos Therapeutics reported its first quarter 2025 financial results, indicating an 8% increase in product revenue year-over-year despite a revenue decline overall. The company is transitioning from a legacy service model to direct sales of its patented treatments for obstructive sleep apnea. Notably, Vivos announced its acquisition of The Sleep Center of Nevada, enhancing its market presence. Despite a slight increase in net loss, Vivos aims to leverage this strategic shift to drive future growth and patient access.
Read more →VVOSVivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. has announced the release date for its first quarter 2025 financial results, set for May 15, 2025. A conference call will accompany the release to discuss the results and company developments. Vivos specializes in proprietary treatments for sleep-related breathing disorders, with a focus on obstructive sleep apnea. The company highlights its innovative non-invasive solutions and aims to address the complex needs of affected patients.
Read more →VVOS▼ -5%on this news
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands
Vivos Therapeutics has announced a definitive agreement to acquire The Sleep Center of Nevada, expanding its treatment accessibility for obstructive sleep apnea (OSA) in the Las Vegas area. The acquisition is anticipated to close in the coming quarter, enhancing Vivos' strategic alliance and marketing model for delivering its FDA-cleared treatments. The deal, valued at up to $9 million, is expected to significantly increase Vivos' patient base and revenues as they leverage the sleep center's established infrastructure and patient flow.
Read more →VVOSVivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel Precision Radionuclide Therapy™
Vivos Inc. has reported continued progress in its human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India, successfully treating ten patients and establishing a strong safety profile. The therapy has shown promising efficacy, particularly in high-risk tumor locations. Vivos is also laying the groundwork for a permanent operational presence in India, with plans for a corporate office and manufacturing facility. The company aims to enhance the therapy's visibility among oncologists and submit regulatory data to the FDA, while acknowledging potential challenges with the U.S. regulatory landscape.
Read more →VVOS▼ -8.4%on this news
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Man
Vivos Therapeutics reported a strong financial performance for the year 2024, with a 26% increase in product revenue to $15 million and a 21% reduction in operating expenses. This resulted in a significant decrease in operating loss of 35%, down to $11.2 million. Additionally, the company secured FDA clearance for its DNA appliance for treating obstructive sleep apnea in children, marking a pivotal expansion of its product line. Vivos is now pivoting its sales strategy to focus on provider alliances, potentially enhancing its market penetration and revenue growth.
Read more →VVOSVivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call
Vivos Therapeutics, Inc. has announced its plans to release full year 2024 financial results on March 31, 2025, along with a conference call scheduled for 5:00 p.m. (ET). The call will review financial outcomes and recent developments. Vivos focuses on innovative treatments for sleep-related breathing disorders, having treated numerous patients with its proprietary Vivos Method. However, the company faces potential risks including regulatory scrutiny and uncertainties in achieving future growth.
Read more →VVOS▲ +10.9%on this news
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide
Vivos Therapeutics has announced the expansion of its strategic alliance with Rebis Health into two new locations in Colorado, aiming to improve the availability of its Vivos CARE treatment for obstructive sleep apnea (OSA). The alliance has shown promising initial results, with a 2:1 preference for Vivos treatments over traditional CPAP therapy among patients. Additionally, Vivos is looking to further strengthen its market presence through potential acquisitions of sleep medicine practices nationwide. The company anticipates substantial revenue growth and improved profit margins from this new alliance model.
Read more →VVOS▼ -11.5%on this news· ran to -22% by day 3
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.
Vivos Therapeutics, Inc. will participate in a fireside chat hosted by Water Tower Research on February 18, 2025. The discussion will feature CEO Kirk Huntsman, who will outline the company's strategic shift towards a medical-based business model and detail the Vivos CARE devices designed for treating sleep-related breathing disorders. The chat aims to provide insights into the OSA market dynamics and Vivos's ongoing initiatives to establish partnerships with sleep treatment providers.
Read more →VVOSVivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
Vivos Inc. has reported promising results from its initial human clinical trials for RadioGel Precision Radionuclide Therapy, demonstrating safety and an encouraging 80% reduction in tumor size for a patient. The company plans to expand its trial size from 30 to 50 patients to gather more data on various cancers, supported by new deep injection technology. Furthermore, Vivos is enhancing its production capacity through collaborations aimed at global expansion. The results will be submitted for publication and shared with the FDA to support further development of RadioGel.
Read more →VVOSVivos Inc.’s IsoPet Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide
Vivos Inc.'s IsoPet division has seen exceptional growth throughout 2024, bolstering its position in the field of veterinary cancer care. The dedicated division launched successfully, expanded its network of certified clinics from 8 to 13, and introduced innovative treatment techniques. A nationwide marketing campaign increased community engagement, emphasizing IsoPet's advanced cancer treatments. Moving forward, IsoPet plans to further expand its clinic network and continue its collaboration with veterinary institutions.
Read more →VVOSVivos Inc. Announces Launch of Groundbreaking RadioGel Precision Radionuclide Therapy™ Human Clinical Trial
Vivos Inc. has announced the launch of its first human clinical trial for RadioGel Precision Radionuclide Therapy™ in India, successfully treating five patients with cancerous lymph nodes. This trial aligns with protocols planned for a study at the Mayo Clinic in the U.S. and aims to demonstrate the therapy's safety. The company has received regulatory approvals to expand the trial to 30 patients. Further trial results will be submitted to reinforce RadioGel's safety profile for a potential U.S. introduction.
Read more →VVOSVivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Vivos Therapeutics has announced a $3.5 million registered direct offering, pricing 709,220 shares of common stock at $4.935 each. This offering is conducted under Nasdaq rules and will close around December 24, 2024, pending closing conditions. Additionally, short-term warrants to purchase the same number of shares at $4.81 each will be issued. The funds raised will be allocated towards working capital and corporate purposes. Vivos, specializing in treatments for obstructive sleep apnea, aims to bolster its financial position through this capital increase.
Read more →VVOSVivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm
Vivos Therapeutics, Inc. reported its third quarter 2024 financial results, highlighting a 17% increase in revenue from the previous quarter, totaling $3.9 million. The company also achieved a 27% reduction in operating loss due to effective cost management, marking nine consecutive quarters of decreasing operating expenses. Notably, Vivos received FDA 510(k) clearance for a device aimed at treating moderate to severe obstructive sleep apnea in children, alongside new CPT codes from the AMA expected to enhance device usage. Management anticipates reaching positive cash flow from operations by mid-2025 as it expands its marketing efforts.
Read more →VVOSVivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
Vivos Therapeutics, Inc. has announced its plans to release its third quarter 2024 financial results on November 14, 2024, followed by a conference call. The call, scheduled for 5:00 p.m. Eastern Time, will review the financial results and share an overview of recent company developments. Vivos is known for its innovative treatments for sleep-related breathing disorders, having successfully treated over 47,000 patients with its proprietary methods. The company also warns of potential risks related to revenues and patient outcomes.
Read more →VVOS▲ +9.4%on this news
Vivos Inc. Certifies New Clinic for IsoPet Precision Radionuclide TherapyTM
Vivos Inc. has certified a new clinic, NorthStar Vets, to provide IsoPet Precision Radionuclide Therapy for small animals, specifically targeting cancer treatment. The certification is designed to lower costs for clinics looking to provide this therapy, which utilizes a proprietary hydrogel technology to deliver localized radiation directly to tumors. This significant expansion is part of Vivos' effort to increase the number of clinics certified in IsoPet therapy, potentially improving treatment access for pets with cancer. The company continues to explore partnerships and revenue opportunities with both veterinary hospitals and private clinics.
Read more →VVOSVivos Therapeutics Granted CPT Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
Vivos Therapeutics, Inc. has announced that the American Medical Association has issued new CPT codes for its CARE oral medical devices, effective January 1, 2025. This development is expected to enhance insurance coverage and reimbursement for patients suffering from obstructive sleep apnea (OSA). Vivos believes that these changes will allow more patients to access their FDA-cleared treatments and heralds a significant step towards making OSA treatments more available and affordable. The company is optimistic that this approval, coupled with recent regulatory milestones, will bolster its growth and market presence.
Read more →VVOSVivos Inc. Extended its IsoPet Precision Radionuclide TherapyTM to Exotics
Vivos Inc. has successfully extended its IsoPet Precision Radionuclide Therapy to exotic animals, starting with the treatment of a ferret that showed a notable reduction in tumor size after three weeks. This innovative therapy addresses the limited cancer treatment options currently available for small exotic pets and aims to provide a safer alternative to invasive surgical procedures. The company's technology uses localized radiation to effectively target tumors while minimizing exposure to surrounding tissues.
Read more →VVOS▼ -22%on this news
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Vivos Therapeutics has announced the pricing of a registered direct offering of common stock amounting to $4.3 million. The company has entered into agreements with institutional investors to sell approximately 1,363,812 shares at a price of $3.15 each. The anticipated gross proceeds will support the company's working capital and general corporate purposes. The closing of this offering is expected to take place around September 20, 2024, pending customary closing conditions.
Read more →VVOS▲ +47.5%on this newsshared move
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market
Vivos Therapeutics has achieved a significant milestone by obtaining FDA 510(k) clearance for its DNA appliance, the first oral medical device approved to treat moderate to severe obstructive sleep apnea and snoring in children aged 6 to 17. This landmark clearance not only introduces a novel non-invasive treatment option but also positions Vivos to capture a share of the growing pediatric obstructive sleep apnea market. The device is reported to effectively reduce nighttime snoring and improve airway volume, which can benefit millions of affected children. Vivos is set to leverage this FDA approval as it integrates pediatric care into its distribution model, hoping to enhance its revenue and market presence.
Read more →VVOSVivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
Vivos Therapeutics, Inc. announced its plans to release financial results for the second quarter of 2024 after market close on August 14, 2024. The company will host a conference call to discuss these results, alongside recent achievements and developments. Vivos specializes in treatments for sleep-related breathing disorders and has achieved notable success with its proprietary Vivos Method, which has treated over 45,000 patients worldwide. However, the company faces risks related to marketing strategies, regulatory scrutiny, and patient outcomes.
Read more →VVOSVivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quar
Vivos Therapeutics reported its financial results for the second quarter of 2024, showcasing a 19% increase in revenue, attributed to higher sales and successful cost-cutting initiatives that reduced operating expenses by 31%. The company noted significant improvements over the previous year, including a decrease in operating loss and an increase in gross margin. Vivos is expanding its market presence through strategic alliances for distribution, which they anticipate will enhance their revenue growth further. Overall, the company's proactive measures position them for achieving positive cash flow by early 2025.
Read more →VVOS▼ -5%on this news
Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA
Vivos Inc. announced an update regarding its Investigational Device Exemption (IDE) submission, revealing that the FDA has accepted the company's conversion to a Pre-Sub filing. This decision allows Vivos to comprehensively address FDA feedback and maintain communication through expedited review sessions. The company is confident in the information provided so far and anticipates submitting a refined application within 45 days. Additionally, Vivos is preparing to collaborate with Mayo Clinic for a treatment plan targeting solid metastatic tumors in lymph nodes associated with thyroid cancer.
Read more →VVOS▼ -7.1%on this news
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Vivos Inc. has submitted an Investigational Device Exemption (IDE) application to the FDA to begin human clinical trials following their Breakthrough Device Designation for RadioGel™. This application addresses 63 comments received from the FDA on a previous submission and includes results from studies on RadioGel® genotoxicity and retention in tumor sites. The company aims to collaborate with the Mayo Clinic to target solid metastatic tumors in lymph nodes related to papillary thyroid cancer. Vivos Inc. remains ready to promptly address any further comments from FDA reviewers.
Read more →VVOS▲ +9.6%on this newsshared move
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
Vivos Therapeutics announced positive results from a 7-month pilot program testing its new provider-based marketing and distribution model for obstructive sleep apnea (OSA) treatments. In this study, 79% of newly diagnosed adult patients selected Vivos' oral appliance therapy over CPAP options, demonstrating a high acceptance rate. The pilot involved 99 patients across diverse demographics and suggests strong revenue potential for Vivos through partnerships with healthcare providers. Investors expressed confidence in Vivos' improved market strategy as these results signify validation of their business model.
Read more →VVOS▼ -8.2%on this news· ran to -20% by day 3
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in
Vivos Therapeutics announced a $7.5 million equity investment led by Seneca Partners and established a strategic marketing and distribution alliance with a sleep treatment provider in Colorado. This partnership aims to enhance the company's revenue model and expand the availability of its proprietary OSA treatment devices. The collaboration will launch in July 2024 at two sleep treatment centers, providing a comprehensive range of treatment options for OSA patients. The funding is expected to bolster Vivos' cash flow and support its ambitious growth strategy within the sleep disorder market.
Read more →VVOS▲ +23.9%on this news
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarte
Vivos Therapeutics, Inc. reported its financial results for the first quarter of 2024, indicating a revenue of $3.4 million, a decrease from $3.8 million year-over-year. The company has successfully cut operating expenses by 22%, marking the seventh consecutive quarter of reduction, as part of its cost-cutting initiatives. A key highlight is the regulatory approval for Medicare reimbursement for Vivos' CARE oral devices, which is expected to increase patient access and utilization. Despite a drop in revenue from VIP enrollments, Vivos anticipates that new strategic initiatives and favorable market trends will facilitate future revenue growth.
Read more →VVOS▲ +23.9%on this news
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
Vivos Therapeutics, Inc. has scheduled the release of its first quarter 2024 financial results, to be announced after market close on May 14, 2024. The company will host a conference call at 5:00 p.m. ET to discuss the results and share updates on recent developments. With a focus on innovative treatments for sleep-related breathing disorders, Vivos has treated over 42,600 patients globally using its proprietary Vivos Method.
Read more →VVOS▼ -9.1%on this news
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
Vivos Therapeutics has announced that its CARE oral medical devices have received full approval for Medicare reimbursement, marking a significant milestone for the company. This approval allows a vast number of Medicare beneficiaries to access treatment for obstructive sleep apnea (OSA) at potentially lower costs. Vivos' devices are designed to effectively treat all severities of OSA, and this change is expected to enhance accessibility to their therapy for many patients. The approval is viewed as a pivotal moment for Vivos’ market impact and patient care expansion.
Read more →VVOSVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos' Proprietary Ora
Vivos Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting a decrease in revenue alongside significant cost reductions. The company's operating expenses fell by 27% year-over-year, contributing to a net loss reduction. Notably, Vivos received FDA 510(k) clearance for its CARE oral devices, which may drive future revenue growth. The company is optimistic about increasing inquiries and enrollment contracts, signifying a positive trend as it aims for cash flow positive operations by the end of 2024.
Read more →VVOSVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
Vivos Therapeutics, Inc. has announced the release of its fourth quarter and full year 2023 financial results, scheduled for March 28, 2024. The company will hold a conference call to discuss these results as well as recent milestones and developments. Vivos specializes in proprietary treatments for sleep-related breathing disorders, including its clinically effective Vivos Method. The announcement comes with caution regarding potential risks that could affect the company's future performance.
Read more →VVOS▲ +6.1%on this news
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
Vivos Therapeutics has announced the immediate exercise of warrants by an institutional investor, resulting in approximately $4.0 million in gross proceeds. The investor will purchase 980,393 shares at an elevated exercise price, and Vivos will issue new warrants for additional shares. This move is expected to close by February 20, 2024, depending on customary conditions. The net proceeds will be used for general corporate purposes, further showcasing the company's commitment to its growth and operational strategies.
Read more →VVOSVivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
Vivos Therapeutics, Inc. announced favorable market developments, including FDA clearance for its CARE appliances to treat severe obstructive sleep apnea (OSA). This comes as Philips Respironics has suspended sales due to safety concerns, creating a significant opportunity for Vivos to expand its user base. United Healthcare's new policy requiring oral appliance therapy before surgical treatments also positions Vivos favorably in the market. The company anticipates increased revenue as patients seek alternatives to CPAP devices.
Read more →VVOSVivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
Vivos Therapeutics has reported a substantial increase in interest and orders for its CARE oral medical devices following FDA 510(k) clearance to treat severe obstructive sleep apnea (OSA). New inquiries from dentists surged by 600% in December, and signed enrollment contracts rose by 38%. Additionally, orders for the CARE devices increased 26% over the prior sales average. The company anticipates continuing momentum into 2024, although there are uncertainties regarding future revenue and patient outcomes.
Read more →VVOS▼ -14.4%on this news· ran to -35% by day 3
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
Vivos Therapeutics, Inc. is hosting the "Empowering Women to Champion Airway" conference on February 1-2, 2024, in Denver, CO. This event aims to unite women professionals in medical and dental fields to emphasize airway health's importance. Recently, Vivos received FDA 510(k) clearance for their CARE oral appliances, presenting a new treatment option for severe obstructive sleep apnea. The event highlights the need for collaboration among healthcare providers to improve patient outcomes in airway management.
Read more →VVOS▲ +833.9%on this news
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
Vivos Therapeutics has received the first-ever FDA 510(k) clearance for an oral device specifically for treating severe obstructive sleep apnea in adults. This clearance allows Vivos to market alternative treatments to CPAP and surgical options, with clinical data showing that 80% of patients experienced significant improvements. The company anticipates that this approval will enhance acceptance among medical professionals and potentially lead to higher patient referrals and revenues. The innovative CARE appliances offer a non-invasive alternative, marking a significant advancement in the treatment landscape for OSA.
Read more →VVOS▲ +9.7%on this news
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
Vivos Therapeutics reported a decrease in revenue for the third quarter of 2023, with operating expenses down significantly due to cost-cutting measures. The company expanded its strategic partnerships, including a nationwide distribution agreement with Lincare, anticipated to enhance revenue. However, it has faced challenges such as lower product sales and governmental investigations impacting new case starts. Cash flow improvements were noted following a successful private placement, aiming for cash flow positivity in the upcoming year.
Read more →VVOS▼ -11.6%on this newsshared move
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
Vivos Therapeutics plans to release its third quarter 2023 financial results after market close on November 14, 2023. The company will host a conference call the same day at 5:00 p.m. ET to discuss these results and recent developments. Vivos focuses on innovative treatments for obstructive sleep apnea and dentofacial abnormalities, offering noninvasive solutions. Their method has been used effectively on around 40,000 patients worldwide, demonstrating their credibility in the field.
Read more →VVOS▲ +7.1%on this news
Vivos Therapeutics Closes $4 Million Private Placement
Vivos Therapeutics, a medical technology company, announced the closure of a $4 million private placement, which is intended to provide approximately $3.5 million in net proceeds for working capital. The placement involves the issuance of shares and warrants to a single institutional investor. While the company sees potential for additional capital through the warrants, there are no assurances regarding their future exercise. Vivos plans to file a registration statement to cover the resale of securities issued, enhancing its operational capacity.
Read more →VVOS▼ -16.2%on this newsshared move
Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vivos Therapeutics has announced a $4 million private placement of common stock with an institutional investor, priced at $4.08 per share. The closing of the placement is expected on or about November 2, 2023, subject to standard conditions. The funds raised will be utilized for general corporate purposes, affirming the company's commitment to its innovative treatments for dentofacial abnormalities and obstructive sleep apnea. Vivos also plans to amend an existing stock purchase warrant to facilitate this transaction.
Read more →VVOS▼ -6.9%on this news· ran to -54% by day 3shared move
Vivos Therapeutics Announces Reverse Stock Split
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has announced a 1-for-25 reverse stock split effective October 27, 2023. This decision, approved by stockholders on September 22, 2023, aims to comply with Nasdaq's minimum bid price requirement and to enhance the attractiveness of the stock to institutional investors. The split will reduce the number of outstanding shares significantly while maintaining the ownership percentage for existing shareholders. Adjustments will also be made to the company's equity incentive plans and warrant exercise prices as a result of the split.
Read more →VVOS▼ -5.8%on this news· ran to -38% by day 3shared move
Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
Vivos Therapeutics has signed a nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products. This agreement follows a successful pilot program and allows Lincare six months of exclusivity to distribute certain Vivos devices. The partnership aims to provide alternative solutions for sleep apnea patients who are non-compliant with CPAP treatments. Vivos plans to extend its collaboration with Lincare across additional major markets over the coming months.
Read more →VVOSVivos Therapeutics to Begin Clinical Trial at Stanford Medicine
Vivos Therapeutics, a company focused on innovative treatments for obstructive sleep apnea (OSA), announced the commencement of a clinical trial of its DNA appliance at Stanford Medicine, with participant enrollment set to start in early 2024. This trial aims to compare the DNA appliance's efficacy against the standard CPAP treatment in patients with moderate to severe OSA. The DNA appliance has recently received FDA clearance for treating mild-to-moderate OSA, and prior studies have indicated positive results, including substantial reductions in the apnea-hypopnea index. However, the trial's success depends on various factors, including participant enrollment and the outcomes of the study itself.
Read more →VVOS▲ +6.9%on this news
Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion
Vivos Therapeutics has announced a strategic collaboration with NOUM DMCC, a Dubai-based healthcare company, granting exclusive distribution rights for its products in the MENA region. This partnership aims to address the rising demand for effective alternatives to CPAP therapy among patients with sleep disorders. Vivos anticipates that revenue from this collaboration may begin as soon as 2024, following regulatory approvals. The venture marks a significant step in Vivos' international expansion efforts, leveraging Noum's established relationships within the regional healthcare market.
Read more →VVOS▲ +64.6%on this news· ran to +76% by day 1shared move
Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers
Vivos Therapeutics has formed strategic partnerships with Ormco and On Demand Orthodontist to enhance its service offerings and revenue generation. These agreements will allow Vivos providers to use Spark™ Clear Aligners, which are gaining popularity in the orthodontic field. The collaboration is anticipated to lead to improved treatment outcomes, as Vivos CARE devices will be used alongside Spark Aligners. These initiatives highlight Vivos' commitment to providing effective solutions for its patient base and enhancing the capabilities of its providers.
Read more →VVOS▲ +5.1%on this news· ran to -15% by day 3
Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update Operating Expenses Decreased 31% Quarter Over Quarter and 25% Year to Date, Reflecting Cost Cutting Initiatives Management
Vivos Therapeutics reported its financial results for the second quarter of 2023, showing a decrease in revenue and an overall net loss despite a significant reduction in operating expenses. The company attributed the revenue decline to lower product sales and negative impacts from external factors, including legal issues surrounding competitors. Vivos has implemented cost-cutting initiatives to streamline operations and aims to achieve cash flow positivity by early 2024; however, it may require additional financing to continue its efforts. The company continues to expand its product line and explore new revenue opportunities, especially in partnerships with Dental Service Organizations and distribution agreements.
Read more →VVOS▲ +5.1%on this news· ran to -15% by day 3
Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call
Vivos Therapeutics, Inc. has announced the rescheduling of its second quarter 2023 financial results conference call to August 16, 2023. The delay was attributed to the need for additional time to review accounting disclosures related to the Employee Retention Tax Credit. The company plans to discuss its financial results, as well as recent milestones and developments, during the call. Vivos focuses on innovative treatment methods for breathing and sleep conditions associated with dentofacial abnormalities.
Read more →VVOSVivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call
Vivos Therapeutics, Inc. announced the postponement of its conference call to discuss financial results for the second quarter of 2023. The delay is attributed to the company's need for additional time to review accounting disclosures related to its Employee Retention Credit. Vivos is working diligently and aims to file its Form 10-Q within the five-day extension period allowed by Rule 12b-25. Further details regarding the financial conference call will be provided in a future announcement.
Read more →VVOSVivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call
Vivos Therapeutics plans to release its second quarter 2023 financial results after market close on August 14, 2023, followed by a conference call at 5:00 p.m. Eastern Time. The call will discuss the company's recent milestones and developments in innovative treatment methods for sleep-related issues. Vivos has established itself in the market with its noninvasive and cost-effective solutions for mild to moderate obstructive sleep apnea, having treated around 40,000 patients globally.
Read more →VVOS▲ +13.3%on this news
Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update Revenue increased 6% Year-Over-Year; Operating Expenses Decreased 20% as Cost Cutting Initiatives Take Hold Management to Ho
Vivos Therapeutics, Inc. reported a 6% increase in revenue for Q1 2023, totaling $3.9 million, primarily driven by higher provider enrollments and seminar revenues. Operating expenses decreased by 20% due to implemented cost-cutting initiatives, contributing to a reduced net loss. The company highlighted its growth strategy, including an asset acquisition from Advanced Facialdontics and developments in its Vivos Method for treating sleep issues. With over 35,000 patients treated, Vivos expressed optimism about achieving cash flow positivity by Q1 2024.
Read more →VVOSVivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call
Vivos Therapeutics has scheduled its first quarter 2023 financial results release for June 8, 2023, followed by a conference call at 5:00 PM ET to discuss the results and recent company developments. The conference call will be accessible to investors, with a replay option available after the event. Vivos specializes in developing diagnostic and treatment methods for patients with sleep-related health conditions linked to dentofacial abnormalities.
Read more →VVOSVivos Therapeutics Announces Additional Strategic Initiatives Aimed at Accelerating Anticipated Timeline for Cash Flow Positive Operations Moss Adams LLP also appointed as new independent registered public accounting fir
Vivos Therapeutics has announced a series of strategic initiatives designed to enhance operational efficiency and accelerate the timeline for reaching positive cash flow by one quarter, now anticipated in Q1 2024. Key measures include significant expense reductions, the expansion of their product suite, and an approximate 17% workforce reduction. Additionally, the company appointed Moss Adams LLP as its new independent registered public accounting firm following the dismissal of Plante & Moran, PLLC. These changes come as Vivos aims to navigate challenges posed by the pandemic while improving its financial stability.
Read more →VVOS▲ +9%on this news
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call
Vivos Therapeutics, Inc. has announced the scheduling of its fourth quarter and full year 2022 financial results, set to be released after market close on March 30, 2023. A conference call will follow at 5:00 PM Eastern Time to discuss these results and recent developments within the company. Vivos continues to focus on innovative solutions for treating breathing-related sleep disorders, showcasing its Vivos Method with a solid track record of patient effectiveness.
Read more →VVOS▲ +9%on this news
Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update 2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition,
Vivos Therapeutics, a medical device and technology company, reported its financial results for Q4 and the full year of 2022, highlighting a capital raise of $7.4 million and operational advancements. The firm noted a year-on-year revenue decrease, impacted by revenue recognition policy changes, but saw growth in appliance sales and patient treatments. Key achievements included FDA clearance for its DNA appliance and patent acquisitions from Advanced Facialdontics to enhance its portfolio. Moving forward, Vivos aims to leverage these developments to boost market penetration and create diverse revenue streams.
Read more →VVOS▼ -5.1%on this news
Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference
Vivos Therapeutics, Inc. announced its participation in the 35th Annual ROTH Conference, where CEO Kirk Huntsman and CFO Brad Amman will engage in discussions and meetings with investors. The virtual and in-person conference, occurring from March 12-14, 2023, will feature various industry panels and presentations. Vivos Therapeutics specializes in developing innovative treatments for breathing-related sleep disorders, particularly through its proprietary Vivos Method. The event may bolster the company's profile and connectivity with investors.
Read more →VVOS▼ -27.9%on this news
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC
Vivos Therapeutics has announced the acquisition of product rights and patents from Advanced Facialdontics, which includes two FDA-cleared products for treating conditions associated with obstructive sleep apnea and other dental issues. This acquisition enhances Vivos's product line and revenue potential by adding effective treatment options for patients suffering from temporomandibular joint dysfunction and bruxism. The deal also bolsters Vivos's intellectual property portfolio and enables them to better serve a broader range of patient needs. Dr. Scott Simonetti, the inventor of the acquired patents, will join Vivos as Senior Director of Research and Product Development.
Read more →VVOS▼ -27.9%on this news
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC Acquisition Adds Complementary, Lower Cost Products for
Vivos Therapeutics has announced the acquisition of patents and product rights from Advanced Facialdontics, which enhances its offerings for treating obstructive sleep apnea (OSA) and related conditions. This acquisition includes innovative technologies and lower-cost products ideal for patients suffering from TMD and bruxism. The acquisition aims to open new markets and increase revenue potential, allowing Vivos to provide a broader range of treatment options. Dr. Scott Simonetti, founder of Advanced Facialdontics, will lead research and product development at Vivos following this acquisition.
Read more →VVOS▼ -5.7%on this news· ran to -24% by day 3
Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
Vivos Therapeutics, Inc. will present at the Emerging Growth Conference on February 22, 2023, at 12:35 pm ET. Kirk Huntsman, the company's Chairman and CEO, will discuss Vivos' innovative treatments for sleep-disordered breathing, including obstructive sleep apnea. Interested investors can attend the real-time presentation either live or via replay on Vivos' website. The conference aims to connect public companies with a broad investment audience.
Read more →VVOS▼ -9.3%on this news
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements
Vivos Therapeutics, Inc. has announced that it has regained compliance with the Nasdaq minimum bid price requirements, closing an earlier non-compliance issue. The company had previously been notified of its non-compliance due to a failure to maintain a closing bid price of $1.00 for 30 consecutive days. After meeting the necessary criteria, Vivos is now in compliance with all applicable Nasdaq listing standards, with this matter considered closed by Nasdaq. The company is focused on innovative treatments for patients with obstructive sleep apnea and dentofacial abnormalities.
Read more →VVOS▼ -5.9%on this news
Vivos Therapeutics Closes $8 Million Private Placement
Vivos Therapeutics, Inc. announced the closing of an $8 million private placement with a single institutional investor. Net proceeds for the company are expected to be approximately $7.4 million, which will be used for general working capital and corporate purposes. The offering comprised common stock shares, pre-funded warrants, and warrants at a purchase price of $1.20 per share. The transaction will also lead to the filing of a resale registration statement with the SEC within 30 days.
Read more →VVOSVivos Therapeutics Announces Pricing of $8 Million Private Placement
Vivos Therapeutics has announced a private placement offering to raise approximately $8 million. Each unit in the offering consists of one share of common stock and a warrant exercisable at a price of $1.20 per share. The company expects to receive about $7.5 million after fees and expenses, with the closing anticipated on January 9, 2023. This move is part of Vivos' strategy to develop innovative treatments for obstructive sleep apnea and related conditions.
Read more →VVOS▲ +154.1%on this newsshared move
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea
Vivos Therapeutics has received FDA 510(k) clearance for its DNA oral appliance, representing a new treatment for mild-to-moderate obstructive sleep apnea (OSA). This breakthrough device is expected to enhance patient outcomes by addressing the underlying causes of OSA. High satisfaction rates in clinical studies suggest significant patient approval and effectiveness, positioning Vivos favorably in the OSA treatment market. The DNA appliance may provide a non-invasive alternative to traditional treatments like CPAP, enhancing patient comfort and compliance.
Read more →VVOS▲ +14.1%on this news
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update Second and Third Quarter 10-Q Filings Bring Vivos Current on SEC Filings for Nasdaq Stock M
Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update and Third Quarter 10-Q Filings Bring Vivos Current on SEC Filings for Nasdaq Stock Market Purposes to Host Conference Call Today at 5:00 pm ET Colo., December 20, 2022 - Vivo
Read more →VVOS▲ +14.1%on this news
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update
Second and Third Quarter 10-Q Filings Bring Vivos Current on SEC Filings for Nasdaq Stock Market Purposes Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VV
Read more →VVOS▲ +5.1%on this news· ran to +33% by day 1shared move
Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call
HIGHLANDS RANCH, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate ob
Read more →VVOSVivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems
LITTLETON, Colo., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new revenues starting immedia
Read more →VVOSVivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q Vivos expects to become current on its SEC filings in the coming weeks LITTLETON, COLOR
Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q expects to become current on its SEC filings in the coming weeks COLORADO-November 28, 2022-Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Co
Read more →VVOS▲ +9.7%on this newsshared move
Vivos Therapeutics Provides Update on Revenue Recognition Review Detailed Analysis Finds Minimal Impact on Prior Financial Results; No Previously Reported Revenue to be Lost Previously Reported First Quarter 2022 Revenue
Therapeutics Provides Update on Revenue Recognition Review Analysis Finds Minimal Impact on Prior Financial Results; No Previously Reported Revenue to be Lost Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000; No Need to Restate Prior Year Finan
Read more →VVOSVivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company t
Read more →VVOSVivos Therapeutics Provides Update on Second Quarter Earnings Delay
LITTLETON, Colo., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is providing an update on the delay in announcing its second quarter 2022 financial results. “We are disappointed it is taking longer than usual to report our financial and oper
Read more →VVOS▲ +6%on this news
Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call
LITTLETON, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstruct
Read more →VVOS▼ -6.9%on this news
Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call
LITTLETON, Colo., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstruct
Read more →VVOSVivos Therapeutics Announces Multiple Regulatory Clearances in Australia for its Entire Line of Oral Appliances Australia clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity i
Therapeutics Announces Multiple Regulatory Clearances in Australia for its Entire Line of Oral Appliances clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity in broad regulatory win. COLO., JULY 14, 2022 - Vivos Therapeutics, Inc. (N
Read more →VVOSVivos Therapeutics Announces Exclusive Distribution Agreement with GM Instruments, Ltd. for the U.S. and Canada
LITTLETON, Colo., June 29, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to mode
Read more →VVOS▼ -11.1%on this news
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea
LITTLETON, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to
Read more →VVOSVivos Therapeutics' SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea Study Recently Presented at the SLEEP 2022 Annual Meeting LITTLETON, COLO., J
Therapeutics' SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea Recently Presented at the SLEEP 2022 Annual Meeting COLO., JUNE 14, 2022 - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or "the Company"
Read more →VVOS▲ +6.1%on this news· ran to +26% by day 1
Vivos Therapeutics to Present at Upcoming SLEEP 2022 Annual Meeting
HIGHLANDS RANCH, Colo., May 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofac
Read more →VVOSVivos Therapeutics Reports First Quarter 2022 Financial Results and Operational Update First Quarter Appliance Revenue Increased 19% Year-Over-Year Management to Host Conference Call Today at 5:00 p
Therapeutics Reports First Quarter 2022 Results and Operational Update Quarter Appliance Revenue Increased 19% Year-Over-Year to Host Conference Call Today at 5:00 pm ET RANCH, Colo., May 16, 2022 - Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ: VVOS), a medic
Read more →VVOSVivos Therapeutics Reports First Quarter 2022 Financial Results and Operational Update
First Quarter Appliance Revenue Increased 19% Year-Over-Year Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., May 16, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focuse
Read more →VVOSVivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call
HIGHLANDS RANCH, Colo., April 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dento
Read more →VVOSVivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method
HIGHLANDS RANCH, Colo., April 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos'' or the “Company''), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients with dentofacial abn
Read more →VVOSVivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call
HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dento
Read more →VVOSVivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Manage
Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% to Host Conference Call Today at 5:00 pm ET RANCH, Colo., March 31, 2022 - Vivos Therapeutics, I
Read more →VVOSVivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a med
Read more →VVOS▼ -7.4%on this news· ran to -18% by day 3
Vivos Therapeutics Rebrands Proprietary Clinical Protocol for Treating Patients with Breathing and Sleep Disorders
HIGHLANDS RANCH, Colo., March 03, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dento
Read more →VVOSVivos Therapeutics to Participate in Upcoming Investor Conferences
HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dento
Read more →VVOS▲ +8.9%on this news· ran to +21% by day 3
Vivos Therapeutics to Present at March 2022 World Sleep Congress in Rome
HIGHLANDS RANCH, Colo., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to
Read more →VVOSVivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric
HIGHLANDS RANCH, Colo., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to
Read more →VVOS▲ +41.1%on this news
Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing By Vivos Dentists Using SleepImage Technology
Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test HIGHLANDS RANCH, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS),
Read more →VVOS▼ -7%on this news
Vivos Therapeutics’ mmRNA Oral Appliance Now Eligible for Medicare Reimbursement
mmRNA is the first and only appliance of its kind covered by Medicare Part of the Vivos System treatment, the mmRNA appliance represents a highly effective, non-surgical, non-invasive, and non-pharmaceutical alternative for patients suffering from OSA and snoring HIGHLANDS RANC
Read more →VVOSVivos Therapeutics Announces Registration with Health Canada to Manufacture and Sell Sleep Disorder, Snoring and Sleep Apnea Appliances to Canadian Dentists
HIGHLANDS RANCH, Colo., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to
Read more →VVOS▼ -8%on this news
Vivos Therapeutics to Participate at the Benzinga Global Small Cap Conference
HIGHLANDS RANCH, Colo., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to
Read more →VVOSVivos Therapeutics Reports Third Quarter 2021 Financial Results and Operational Update Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening
Therapeutics Reports Third Quarter 2021 Financial Results Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study to Host
Read more →VVOSVivos Therapeutics Reports Third Quarter 2021 Financial Results and Operational Update
Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Conference Call Today at 5:00 pm ET
Read more →VVOSVivos Therapeutics to Participate at the Q4 Virtual Investor Summit
HIGHLANDS RANCH, Colo., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OS
Read more →VVOSVivos Therapeutics Schedules Third Quarter 2021 Financial Results Conference Call
HIGHLANDS RANCH, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to
Read more →VVOSVivos Therapeutics Announces 2021 Annual Breathing Wellness Conference Presented by The Vivos Institute
HIGHLANDS RANCH, Colo., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to
Read more →VVOS▲ +9.3%on this newsshared move
Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution
HIGHLANDS RANCH, Colo., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to
Read more →VVOSVivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea
HIGHLANDS RANCH, Colo., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sle
Read more →VVOSVivos Therapeutics to Participate at the Benzinga Healthcare Small Cap Conference
HIGHLANDS RANCH, Colo., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-d
Read more →VVOS▼ -6.2%on this news
Vivos Therapeutics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
Vivos management to present at 7:00 am EDT on September 13, 2021 HIGHLANDS RANCH, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for p
Read more →VVOSVivos Therapeutics and Empower Sleep Launch Cooperative Relationship Aimed at Significantly Improving Proper Obstructive Sleep Apnea Diagnosis and Treatment
HIGHLANDS RANCH, Colo., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-di
Read more →VVOSVivos Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 Management to Host Conference Ca
Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 to Host Conference Call Today at 5:00 pm ET RANCH, Colo., August 12, 2021 - Vivos Therapeutics, Inc. ("the Company") (NASDA
Read more →VVOSVivos Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update
Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021 Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company f
Read more →VVOSVivos Therapeutics Schedules Second Quarter 2021 Financial Results Conference Call
Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatme
Read more →VVOSVivos Therapeutics to Participate at the Q3 Virtual Investor Summit
HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-t
Read more →VVOSVivos Therapeutics Opens State of the Art International Training Center In Denver
HIGHLANDS RANCH, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-di
Read more →VVOSVivos Therapeutics Founder & Chief Medical Officer Releases New Book Highlighting His Groundbreaking Work
HIGHLANDS RANCH, Colo., May 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-dis
Read more →VVOSVivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update
HIGHLANDS RANCH, Colo., May 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-diso
Read more →VVOSVivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update Management to Host Conference Call Today at 5:00 pm
Therapeutics Reports First Quarter 2021 Financial Results and Operational Update to Host Conference Call Today at 5:00 pm ET RANCH, Colo., May 17, 2021 - Vivos Therapeutics, Inc. (the "Company" or "Vivos") (NASDAQ:VVOS), a medical technology company focused on developing and
Read more →VVOSVivos Therapeutics Schedules First Quarter 2021 Financial Results Conference Call
HIGHLANDS RANCH, Colo., May 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered bre
Read more →VVOSVivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares RANCH, Colo., May 11, 2021 - Vivos Therapeutics, Inc. (Nasdaq: VVOS) ("Vivos"), a medical technology company focused on developing and commerciali
Read more →VVOSVivos Therapeutics Announces Pricing of $24 Million Follow-On Offering
HIGHLANDS RANCH, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moder
Read more →VVOSVivos Therapeutics Announces Integrative Cardiologist Dr. Mimi Guarneri as New Medical Director of Clinical Education
HIGHLANDS RANCH, Colo., April 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered b
Read more →VVOSVivos Therapeutics to Participate at the Emerging Growth Conference
HIGHLANDS RANCH, Colo., April 12, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-
Read more →VVOSVivos Therapeutics to Launch MyoCorrect Orofacial Myofunctional Therapy Service Vivos to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem w
Therapeutics to Launch MyoCorrect Orofacial Myofunctional Therapy Service to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos RANCH, Colo., March 30, 2021 - Vivos Therapeutics, Inc. (the "Company" or "Viv
Read more →VVOSVivos Therapeutics to Launch MyoCorrect Orofacial Myofunctional Therapy Service
HIGHLANDS RANCH, Colo., March 30, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, incl
Read more →VVOSVivos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Full Year Revenue Increase of 15% Management to Host Conference Call Today at 5:00 pm
Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Year Revenue Increase of 15% to Host Conference Call Today at 5:00 pm ET RANCH, Colo., March 25, 2021 - Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a medic
Read more →VVOSVivos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
Full Year Revenue Increase of 15% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., March 25, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commerc
Read more →VVOSVivos Therapeutics to Participate at the Benzinga Biotech Small Cap Conference
HIGHLANDS RANCH, Colo., March 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-
Read more →VVOSVivos Therapeutics Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for Thursday, March 25, 2021 at 5:00 pm ET
HIGHLANDS RANCH, Colo., March 18, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-
Read more →VVOSVivos Therapeutics to Participate at the Q1 Virtual Investor Summit
Vivos management to present at 1:30 pm Eastern Time on March 23, 2021 HIGHLANDS RANCH, Colo., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing inn
Read more →VVOSVivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center
HIGHLANDS RANCH, Colo., March 08, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-
Read more →VVOSVivos Therapeutics to Participate in the Virtual 33rd Annual ROTH Conference on March 15-17, 2021
HIGHLANDS RANCH, Colo., March 01, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild
Read more →VVOSVivos Therapeutics Launches VivoScore Diagnostic Technology for Home Sleep Apnea Testing in Children and Adults
HIGHLANDS RANCH, Colo., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstru
Read more →VVOSVivos Therapeutics Launches VivoScore Diagnostic Technology for Home Sleep Apnea Testing in Children and Adults VivoScore Opens the Door for More Patients to be Diagnosed and Treated for Sleep Apnea
Therapeutics Launches VivoScore Diagnostic Technology for Sleep Apnea Testing in Children and Adults Opens the Door for More Patients to be Diagnosed and Treated for Sleep Apnea RANCH, Colo., February 16, 2021 - Vivos Therapeutics, Inc. ("the Company") (NASDAQ: VVOS), a medica
Read more →VVOSVivos Therapeutics Submits FDA 510(k) Application for the Vivos mmRNA Oral Appliance
HIGHLANDS RANCH, Colo., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to mode
Read more →VVOSVivos Therapeutics Forms Clinical Advisory Board to Drive Further Growth of Next-Generation Obstructive Sleep Apnea Treatment Efforts
HIGHLANDS RANCH, Colo., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive
Read more →VVOSVivos Therapeutics Launches AireO2 Patient Management Technology to Treat Patients with Obstructive Sleep Apnea
HIGHLANDS RANCH, Colo., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive
Read more →VVOSVivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional RANCH, Colo., Dec. 15, 2020 - Vivos Therapeutics, Inc. ("Vivos") today announced the closing of its initial public offering of 4,025,000 shares of i
Read more →VVOSVivos Therapeutics Announces Pricing of $21M Initial Public Offering
HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced the pricing of its initial public offer
Read more →VVOSVivos Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
HIGHLANDS RANCH, Colorado, Oct. 09, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Vivos Therapeutics, Inc. (“Vivos”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced that is has filed
Read more →Competitive Position
How VVOS ranks across every disease it competes inCompetitive Position is a premium feature
See how VVOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial